



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
0674219827	06/19/84	HADWARY	RAM1032742

JOHN S. SAKS
340 KINGSLAND ST.
MUTLEY, NJ 07112

EXAMINER	
ART UNIT	PAPER NUMBER
129	8

DATE MAILED: 10/28/85

10/28/85

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

This application has been examined Responsive to communication filed on 8/8/85 This action is made final.

A shortened statutory period for response to this action is set to expire 3 month(s), days from the date of this letter.
Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

- 1. Notice of References Cited by Examiner, PTO-892.
- 2. Notice re Patent Drawing, PTO-948.
- 3. Notice of Art Cited by Applicant, PTO-1449
- 4. Notice of informal Patent Application, Form PTO-152
- 5. Information on How to Effect Drawing Changes, PTO-1474
- 6. _____

Part II SUMMARY OF ACTION

- 1. Claims 1-20 are pending in the application.
Of the above, claims _____ are withdrawn from consideration.
- 2. Claims _____ have been cancelled.
- 3. Claims 1, 13, 16 are allowed.
- 4. Claims 2-12, 14-15, 17-20 are rejected.
- 5. Claims _____ are objected to.
- 6. Claims _____ are subject to restriction or election requirement.
- 7. This application has been filed with informal drawings which are acceptable for examination purposes until such time as allowable subject matter is indicated.
- 8. Allowable subject matter having been indicated, formal drawings are required in response to this Office action.
- 9. The corrected or substitute drawings have been received on _____. These drawings are acceptable; not acceptable (see explanation).
- 10. The proposed drawing correction and/or the proposed additional or substitute sheet(s) of drawings, filed on _____, has (have) been approved by the examiner. disapproved by the examiner (see explanation).
- 11. The proposed drawing correction, filed _____, has been approved. disapproved (see explanation). However, the Patent and Trademark Office no longer makes drawing changes. It is now applicant's responsibility to ensure that the drawings are corrected. Corrections MUST be effected in accordance with the instructions set forth on the attached letter "INFORMATION ON HOW TO EFFECT DRAWING CHANGES", PTO-1474.
- 12. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has been received not been received
 been filed in parent application, serial no. _____; filed on _____.
- 13. Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.
- 14. Other

Art Unit 129

Claims 21-23 are cancelled.

Claims 1-20 remain in the application.

Claims 2-12, 14, 15, 17-20 are rejected under 35 U.S.C. 112, first and second paragraphs, as the claimed invention is not described in such full, clear, concise and exact terms as to enable any person skilled in the art to make and use the same, and/or for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 2, 3, 7, 8, 10, 11, 14, 15, 18 and 19 should be corrected in nomenclature to include the position of the lactone, e.g. (25, 35)... dienoic 1,3-lactone.

Claim 4 should include the term "inert" carrier.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification is objected to under 35 U.S.C. 112, first paragraph, as failing to provide an enabling disclosure.

No enablement is seen for the pervention of or treatment of obesity in mammals. Inhibition of pancrease lipase as taught by the specification only increases the excretion of triglycerides. There is no

direct correlation with blood levels, serum level, intra/extracellular levels in adipose tissue of triglycerides and the claimed compounds. Lipid metabolism, cholesterol/triglyceride chemistry is interactive at many points. Absent supporting evidence it is unreasonable, almost incredible to make the leap to ^{the} use of said compounds in the treatment and prevention of obesity from the data at hand. A decrease in the amount *excreted* of a known lipid does not necessarily mean (or imply) changed blood levels, hence changed triglyceride levels in adipose tissue. Weight loss has not, to Examiners' knowledge, been directly correlated with decreased lipid levels absent other factors e.g. decreased calorie intake, exercise etc. It is far clearer that interference with absorption of fats would be useful in the treatment of hyperlipemia. Applicant has not disclosed how enteric lipase which also digests fat from the intestine would be effected. As carbohydrate metabolism also produces triglycerides it is difficult to understand applicants logic in jumping from Point A (lipase interference) to Point D (weight loss) without (a) reduction in blood levels and (b) reduction in intracellular fluid of modified fibroblasts, and ^c (d) decreased total body intake of carbohydrates etc.

Claims 9-12 and 17-20 are rejected under 35 U.S.C. 112, first paragraph, for the reasons set forth in the above objection to the specification.

Art Unit 129

Claims 1, 13 and 16 have been found allowable.

Claims 2, 3, 5-8, 14, 15 are would be allowable if rewritten to overcome the rejection under 35 U.S.C. 112 and to include all of the limitations of the base claim and any intervening claims.

Claim 4 would be allowable if rewritten or amended to overcome the rejection under 35 U.S.C. 112.

As allowable subject matter has been indicated; applicant's response must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP 707.07(a).

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). The practice of automatically extending the shortened statutory period an additional month upon the filing of a timely first response to a final rejection has been discontinued by the Office. See 1021 TMOG 35.

Serial No. 621827


-5-

Art Unit 129


A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 CFR 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ms. Dinner whose telephone number is (703) 557-6566.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 557-3920.


Dinner:ce

10-16-85


GLENNON H. HOLLRAH
SUPERVISORY PATENT EXAMINER
ART UNIT 129